share_log

Raymond James Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $56

Benzinga ·  01:45  · Ratings

Raymond James analyst Steven Seedhouse maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $51 to $56.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment